Teva Pharmaceutical Industries (NYSE:TEVA) Issues FY 2025 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA) updated its FY 2025 earnings guidance on Saturday. The company provided EPS guidance of 2.450-2.650 for the period, compared to the consensus EPS estimate of 2.560. The company issued revenue guidance of $16.8 billion-$17.2 billion, compared to the consensus revenue estimate of $17.2 billion.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on TEVA. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $21.00 to $23.00 in a research note on Monday, May 12th. Bank of America upped their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, May 8th. Barclays decreased their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, January 30th. StockNews.com raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Wednesday, April 23rd. Finally, UBS Group decreased their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $24.43.

Teva Pharmaceutical Industries Stock Up 0.5%

Shares of NYSE:TEVA opened at $16.95 on Friday. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The company has a market cap of $19.22 billion, a PE ratio of -11.69, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. Teva Pharmaceutical Industries has a 52 week low of $12.47 and a 52 week high of $22.80. The firm has a 50 day simple moving average of $15.35 and a 200 day simple moving average of $17.41.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.47 by $0.05. The business had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The firm’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.48 EPS. As a group, research analysts expect that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Teva Pharmaceutical Industries stock. AQR Capital Management LLC raised its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 24.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 23,955 shares of the company’s stock after purchasing an additional 4,732 shares during the quarter. AQR Capital Management LLC’s holdings in Teva Pharmaceutical Industries were worth $368,000 as of its most recent filing with the SEC. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.